Cargando…

Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria

The World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO 2017) included updated criteria for diagnosis and classification of post-transplant lymphoproliferative disorders (PTLDs). This study evaluated the clinicopathologic spectrum using WHO 2017 criteria a...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Rebecca L., Khurana, Arushi, Mwangi, Raphael, Fama, Angelo, Ristow, Kay M., Maurer, Matthew J., Macon, William R., Ansell, Stephen M., Bennani, N. Nora, Kudva, Yogish C., Walker, Randall C., Watt, Kymberly D., Schwab, Thomas R., Kushwaha, Sudhir S., Cerhan, James R., Habermann, Thomas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423401/ https://www.ncbi.nlm.nih.gov/pubmed/34514344 http://dx.doi.org/10.1097/HS9.0000000000000640

Ejemplares similares

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
por: Arushi Khurana, et al.
Publicado: (2021)

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
por: Asleh, Rabea, et al.
Publicado: (2022)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
por: Bock, A., et al.
Publicado: (2022)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Lymphoproliferative lung disorders: clinicopathological aspects
por: Poletti, Venerino, et al.
Publicado: (2013)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Clinicopathologic Features of Lymphoproliferative Neoplasms Involving the Liver
por: Chiang, I, et al.
Publicado: (2022)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma
por: Tracy, S I, et al.
Publicado: (2017)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Human fetal pancreatic islet-like structures as source material to treat type 1 diabetes
por: Ikeda, Yasuhiro, et al.
Publicado: (2013)

HDL Cholesterol Story Is Dead: Long Live HDL!
por: Simha, Vinaya, et al.
Publicado: (2016)

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
por: Goyal, Gaurav, et al.
Publicado: (2020)

Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder
por: Nie, Guangyan, et al.
Publicado: (2022)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

An accurate diagnosis of dermal CD8 (+) lymphoproliferative disorders requires clinicopathological and immunophenotypic correlation
por: Gru, Alejandro A.
Publicado: (2022)

Castleman disease and mimickers: Clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease
por: Nakazato, Yoshimasa, et al.
Publicado: (2022)

Is HOT a Cool Treatment for Type 1 Diabetes?
por: Rajagopalan, Govindarajan, et al.
Publicado: (2012)

GPR40 Modulators: New Kid on the Block
por: Basu, Ananda, et al.
Publicado: (2013)

Oral Lesions and Lymphoproliferative Disorders
por: Castellarin, P., et al.
Publicado: (2010)

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
por: Ravi, Praful, et al.
Publicado: (2018)

Genetic diversity of newly diagnosed follicular lymphoma
por: Asmann, Y W, et al.
Publicado: (2014)

Clinicopathological findings of systemic Epstein-Barr virus-positive T-lymphoproliferative diseases in younger and older adults
por: Wang, Ziyao, et al.
Publicado: (2021)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
por: Desai, Sanjal H., et al.
Publicado: (2022)

Dirofilariasis presenting as scleritis: A report of two cases
por: Kamath, Yogish Subraya, et al.
Publicado: (2020)

Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
por: Kotwal, Anupam, et al.
Publicado: (2019)

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
por: Tracy, Sean I., et al.
Publicado: (2018)

Cardiovascular and Lymphoproliferative Diseases
por: Huston, Sharon M., et al.
Publicado: (2004)

Post-transplant lymphoproliferative disease
por: Dharnidharka, Vikas R., et al.
Publicado: (2009)

Hydroa vacciniforme‐like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China
por: Wang, Xinhua, et al.
Publicado: (2021)

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
por: Krull, Jordan E., et al.
Publicado: (2020)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study
por: Asleh, Rabea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p491i5ukeakg0mgqiq76q38qsh